Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

US Patent 8853412 · Granted Oct 7, 2014

Estimated economic value: $10,376,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Microbial test standard for use in infrared spectrometry2023
Mass spectrometric diagnosis of septicemia2022
GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and ste2022
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Microbial test standard for use in infrared spectrometry2021
Backpack2020
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020